FDA Grants Breakthrough Status to Raludotatug Deruxtecan for CDH6-Expressing Ovarian and Gynecologic Cancers
TL;DR Summary
Raludotatug deruxtecan has received FDA Breakthrough Therapy Designation for treating CDH6-expressing platinum-resistant ovarian, peritoneal, or fallopian tube cancers, based on promising early trial data, marking a significant step in developing new treatments for these difficult-to-treat cancers.
Topics:business#cancer#fda-breakthrough-therapy#healthcare#merck#ovarian-cancer#raludotatug-deruxtecan
- Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Previously Treated with Bevacizumab Merck.com
- The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers CancerNetwork
- Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation Nasdaq
- FDA Grants Breakthrough Status to Raludotatug Deruxtecan in Ovarian Cancer Curetoday
- FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer OncLive
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
11 min
vs 12 min read
Condensed
98%
2,303 → 36 words
Want the full story? Read the original article
Read on Merck.com